Analyst consensus rating
iBio Analyst Rating: Strong Buy
Direct answer
iBio's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.69.
Forecast evidence checked November 12, 2026.
Get free iBio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.82
- Average price target
- $5.69
- High price target
- $7.00
- Low price target
- $4.20
- Low target gap
- +409.6%
- Target upside
- +590.2%
- High target gap
- +749.3%
- Target range width
- 339.7%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for iBio?
iBio has a verified Strong Buy consensus. The same dataset has an average price target of $5.69.
How far are iBio's low and high targets from the recorded price?
The low target implies +409.6%, while the high target implies +749.3%.
How many analysts are included in iBio's consensus?
The verified consensus includes 9 analysts.
How is iBio's target upside or downside calculated?
The average target of $5.69 is divided by the recorded price of $0.82, then one is subtracted to produce +590.2%. This does not guarantee a future return.
When was iBio's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.